nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—Doxazosin—ADRA2A—attention deficit hyperactivity disorder	0.0184	0.52	CrCbGaD
Alfuzosin—Prazosin—ADRA2A—attention deficit hyperactivity disorder	0.017	0.48	CrCbGaD
Alfuzosin—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.0111	0.11	CbGeAlD
Alfuzosin—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.0064	0.0634	CbGeAlD
Alfuzosin—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.00619	0.0613	CbGeAlD
Alfuzosin—KCNH2—forebrain—attention deficit hyperactivity disorder	0.00618	0.0612	CbGeAlD
Alfuzosin—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.00605	0.0599	CbGeAlD
Alfuzosin—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.00596	0.059	CbGeAlD
Alfuzosin—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.00583	0.0577	CbGeAlD
Alfuzosin—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.00541	0.0536	CbGeAlD
Alfuzosin—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.00523	0.0518	CbGeAlD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.0051	0.00591	CbGpPWpGaD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00504	0.00584	CbGpPWpGaD
Alfuzosin—ADRA1B—brain—attention deficit hyperactivity disorder	0.00473	0.0468	CbGeAlD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0047	0.00544	CbGpPWpGaD
Alfuzosin—ADRA1D—brain—attention deficit hyperactivity disorder	0.00463	0.0458	CbGeAlD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00446	0.00517	CbGpPWpGaD
Alfuzosin—ADRA1B—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00441	0.0051	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00434	0.00502	CbGpPWpGaD
Alfuzosin—KCNH2—midbrain—attention deficit hyperactivity disorder	0.00408	0.0404	CbGeAlD
Alfuzosin—ADRA1A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00391	0.00453	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00373	0.00432	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00372	0.00431	CbGpPWpGaD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0037	0.00429	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00361	0.00418	CbGpPWpGaD
Alfuzosin—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.00348	0.0344	CbGeAlD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00347	0.00402	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00347	0.00402	CbGpPWpGaD
Alfuzosin—KCNH2—nervous system—attention deficit hyperactivity disorder	0.00336	0.0332	CbGeAlD
Alfuzosin—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.00335	0.0331	CbGeAlD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00329	0.00381	CbGpPWpGaD
Alfuzosin—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.00327	0.0324	CbGeAlD
Alfuzosin—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.00323	0.032	CbGeAlD
Alfuzosin—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.00316	0.0313	CbGeAlD
Alfuzosin—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00311	0.0036	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00303	0.0035	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00296	0.00343	CbGpPWpGaD
Alfuzosin—ADRA1D—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00296	0.00343	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00294	0.00341	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00273	0.00316	CbGpPWpGaD
Alfuzosin—ADRA1A—brain—attention deficit hyperactivity disorder	0.00266	0.0263	CbGeAlD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00261	0.00302	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00259	0.003	CbGpPWpGaD
Alfuzosin—KCNH2—brain—attention deficit hyperactivity disorder	0.00257	0.0254	CbGeAlD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00254	0.00294	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00252	0.00292	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00251	0.00291	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00246	0.00285	CbGpPWpGaD
Alfuzosin—ADRA1B—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00246	0.00285	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00244	0.00283	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00236	0.00273	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00234	0.00271	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00223	0.00258	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00219	0.00253	CbGpPWpGaD
Alfuzosin—ADRA1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00218	0.00253	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00218	0.00252	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00217	0.00251	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00215	0.00249	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00213	0.00246	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00211	0.00244	CbGpPWpGaD
Alfuzosin—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00208	0.0206	CbGeAlD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00205	0.00238	CbGpPWpGaD
Alfuzosin—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.002	0.0198	CbGeAlD
Alfuzosin—ADRA1D—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00197	0.00229	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00194	0.00225	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00193	0.00224	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00191	0.00221	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00187	0.00217	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0018	0.00208	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00176	0.00204	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00171	0.00197	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00167	0.00193	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00166	0.00193	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00165	0.00191	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00164	0.0019	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00164	0.0019	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00162	0.00187	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00161	0.00186	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00159	0.00184	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00157	0.00182	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00154	0.00178	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00151	0.00175	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00151	0.00175	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00149	0.00173	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00146	0.00169	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00146	0.00169	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00146	0.00169	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00143	0.00166	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00143	0.00165	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00139	0.0016	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00139	0.0016	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00138	0.0016	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00136	0.00158	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00134	0.00156	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00134	0.00155	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00134	0.00155	CbGpPWpGaD
Alfuzosin—ADRA1D—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00133	0.00153	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00132	0.00153	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00132	0.00153	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0013	0.00151	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0013	0.0015	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00128	0.00148	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00125	0.00145	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00125	0.00145	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00123	0.00143	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00123	0.00142	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00121	0.00141	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00119	0.00138	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00119	0.00137	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00119	0.00137	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00117	0.00136	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00117	0.00136	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00116	0.00134	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00115	0.00133	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00113	0.00131	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00113	0.00131	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00113	0.00131	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00112	0.00129	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00129	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00111	0.00129	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00111	0.00129	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.0011	0.00127	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00109	0.00127	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00109	0.00126	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00108	0.00125	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00106	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00105	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00104	0.0012	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00104	0.0012	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00102	0.00119	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00102	0.00119	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00102	0.00118	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00101	0.00117	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.001	0.00116	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000993	0.00115	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000992	0.00115	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000988	0.00114	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000984	0.00114	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000977	0.00113	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000973	0.00113	CbGpPWpGaD
Alfuzosin—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000955	0.00111	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000954	0.0011	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000926	0.00107	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000924	0.00107	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000907	0.00105	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000904	0.00105	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000892	0.00103	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000878	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000876	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000874	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000864	0.001	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000861	0.000997	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00085	0.000984	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00085	0.000984	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000841	0.000974	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000824	0.000954	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000822	0.000952	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000806	0.000933	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000803	0.00093	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000792	0.000917	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000778	0.000901	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000765	0.000885	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000758	0.000877	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000755	0.000874	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000755	0.000874	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000747	0.000865	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000741	0.000858	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000732	0.000847	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000728	0.000843	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000703	0.000814	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000697	0.000807	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000688	0.000797	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000668	0.000774	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000662	0.000767	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000658	0.000762	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000647	0.000749	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000629	0.000728	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000616	0.000713	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000601	0.000696	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000598	0.000693	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000596	0.00069	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000586	0.000679	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000586	0.000679	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000579	0.00067	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000578	0.000669	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000575	0.000666	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000571	0.000661	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000559	0.000647	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000559	0.000647	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000555	0.000642	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00055	0.000636	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000541	0.000627	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000539	0.000624	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000532	0.000616	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000526	0.000609	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000514	0.000595	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000511	0.000592	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000511	0.000591	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000507	0.000587	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000507	0.000587	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000504	0.000583	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000499	0.000578	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000497	0.000575	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000495	0.000573	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000493	0.00057	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00049	0.000567	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000488	0.000565	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000487	0.000563	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000486	0.000563	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00048	0.000556	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000477	0.000553	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000464	0.000537	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000454	0.000526	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000449	0.00052	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000448	0.000518	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000443	0.000513	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000442	0.000511	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000441	0.000511	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00044	0.000509	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000436	0.000505	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000432	0.000501	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000432	0.0005	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000427	0.000494	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000424	0.000491	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000412	0.000477	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000406	0.000471	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000406	0.000471	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000399	0.000462	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000398	0.00046	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000392	0.000454	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000387	0.000449	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000378	0.000437	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000361	0.000418	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000355	0.000411	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000343	0.000397	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000337	0.000391	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00033	0.000382	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00032	0.00037	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000314	0.000364	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000313	0.000363	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00031	0.00036	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.0003	0.000347	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000295	0.000341	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000289	0.000335	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000285	0.00033	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000278	0.000322	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000274	0.000317	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000265	0.000307	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000262	0.000303	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000261	0.000302	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000258	0.000298	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000253	0.000293	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000243	0.000282	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00024	0.000278	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000236	0.000273	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000232	0.000268	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000229	0.000265	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000213	0.000247	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000209	0.000242	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000203	0.000235	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000168	0.000195	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000149	0.000173	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000144	0.000167	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000144	0.000167	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000142	0.000164	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000132	0.000153	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000115	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00011	0.000127	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000107	0.000124	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.91e-05	0.000103	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	8.73e-05	0.000101	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	8.67e-05	0.0001	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.91e-05	9.16e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.75e-05	4.34e-05	CbGpPWpGaD
